Anti-Human/Rat HER2 (neu) Antibody (7.16.4)

Cat. No.: HY-P990238 Purity: 95.00%: Data Sheet
COA

SDS

FAQs
Technical Support

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8⁺ T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer.

For research use only. We do not sell to patients.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) Chemical Structure

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) Featured Recommendations:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Mouse IgG2a kappa

Recommend Isotype Controls

Mouse IgG2a kappa, Isotype Control

Species Reactivity

Human/Rat

IC₅₀ & Target

HER2 (neu)

In Vitro

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (10 mg/kg, i.p., twice a week, for 21 days) significantly delays tumor growth combined with Pyrotinib (HY-104065) in female BALB/c mice bearing TUBO tumors^[1].
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (100 μg, i.p., once daily, from day 13 to day 17) delays tumor growth in female BALB/c mice bearing TUBO tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5×10⁵ TUBO cells injected female BALB/c mice (5 weeks)^[1]
Dosage:	10 mg/kg, combined with Pyrotinib (10 mg/kg, p.o., 5 times a week)
Administration:	Intraperitoneal injection (i.p.), twice a week, for 21 days
Result:	Significantly inhibited tumor volume. Significantly inhibited the HER2 signaling pathway (downregulation of pHER2, pAKT, pERK). Reduced tumor cell proliferation. Did not significantly affect the weight of mice.

Animal Model:	8×10⁵ TUBO cells injected female BALB/c mice (6-8 weeks)^[2]
Dosage:	100 μg
Administration:	Intraperitoneal injection (i.p.), once daily from day 13 to day 17
Result:	Delayed tumor growth, but could not completely eliminate the tumor. Increased the proportion of PD-1⁺ CD8⁺ T cells.

Gene ID

24337 [NCBI]

Accession

AAH61863

Application

ELISA, FACS, Functional assay, Research in vivo

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Human/Rat HER2 (neu) Antibody (7.16.4)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 95.00%

Select Batch:

Data Sheet (262 KB) SDS (251 KB)

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Liu S, et al. Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. EBioMedicine. 2024 Nov;109:105379. [Content Brief]

[2]. Xu M, Du X, Liu M, Li S, Li X, Fu YX, Wang S. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 2012 Jun;3(6):441-9. [Content Brief]

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Human/Rat HER2 (neu) Antibody (7.16.4)EGFREpidermal growth factor receptorErbB-1HER1HER2CD8T cellsTUBOInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *